drugset

drugset / Trial / NCT01287325

Efficacy of DNK333 in Patients With COPD and Cough

NCT01287325 ↗

Phase 1/2 Completed 28 enrolled Novartis

RandomizedCrossoverTriple-blindTreatment

Summary

This study evaluates the efficacy and safety of two weeks treatment of DNK333 in patients with COPD and cough.

Timeline

Start: 2003-09
Primary completion: 2004-04
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DNK333	Small molecule	100 mg	—

Indications